Lab Manager | Run Your Lab Like a Business

Product News

New Purpose-Built MaxSpec™ Standards Available for Quantitative Mass Spectrometry Analysis

Quantitative lipid standards are prepared specifically for mass spectrometry applications

by Cayman Chemical Company
Register for free to listen to this article
Listen with Speechify

maxspecAnn Arbor, Michigan – April 16, 2018, Cayman Chemical has launched a new line of ready-to-use, quantitative lipid standards prepared specifically for mass spectrometry applications. This new line of MaxSpec™ analytical standards complements Cayman’s high-purity, basic research tools that researchers have been using for more than 37 years. All MaxSpec™ standards are provided in solution and formulated to save time when preparing standards and samples for analysis. To ensure consistency and stability for the life of the product, these standards are prepared gravimetrically, supplied in a deactivated glass ampule, and sealed under argon. The concentration of each MaxSpec™ standard is verified by comparison to an independently prepared calibration standard and guaranteed to meet identity, purity, stability, and concentration specifications detailed on the batch-specific Certificate of Analysis. Ongoing stability testing is performed to ensure the concentration remains accurate throughout the shelf life of the product. To meet the requirement of modern quantitative applications, these MaxSpec™ standards will be made available as single standards, mixtures, and sets.

Lipidomics is a growing field and researchers in many disciplines have an increasing need for highly pure, ready-to-use analytical standards. MaxSpec™ products meet this need by offering researchers a quick and easy solution for preparing standards in mass spectrometry applications. Dr. Paul Kennedy, the director of Cayman’s analytical chemistry division, remarked that “Cayman is well known for the high quality of their analytical standards, especially in the fields of forensic and bioactive lipid science. As mass spectrometry becomes more accessible to the basic researcher, Cayman is committed to supporting them with tools that are purpose built for their applications. Issues such as quantitative accuracy and interlaboratory reproducibility are important concerns that we are engaged in addressing as a trusted supplier of standards, kits, and services.” More than thirty MaxSpec™ standards of key bioactive lipids are currently available, with more products projected to be added by the end of the year.

In tandem with individual standards, mixtures, and sets, several MaxSpec derivatization kits, including the AMP+ MaxSpec™ Kit, Dienes Derivatization MaxSpec™ Kit, and Oxysterol Derivatization MaxSpec™ Kit are also ready for use. These kits package together complete solutions to accelerate workflows and streamline sample and standard preparation in mass spectrometry applications. MaxSpec™ kits are purpose built for mass spectrometry applications and each lot of kits undergoes rigorous testing to ensure consistent performance. These kits contain all necessary reagents including a detailed protocol to simplify workflows and to help improve consistency and reproducibility from run-to-run. Additional MaxSpec™ kits will be made available to aid with mass spectrometry sample preparation and quantification.

About Cayman Chemical Company
Cayman Chemical Company helps make research possible by supplying scientists worldwide with biochemical tools used to understand cancer, neurochemistry, oxidative injury, endocrinology, atherosclerosis, and other human health challenges. Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others for use as research reagents and qualified standards. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination. In addition, we offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques. Cayman performs generic drug development and production in both Ann Arbor, Michigan and Neratovice, Czech Republic.